Epigenetics and cancer treatment
- 15 October 2009
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 625 (1-3), 131-142
- https://doi.org/10.1016/j.ejphar.2009.10.011
Abstract
No abstract availableKeywords
This publication has 159 references indexed in Scilit:
- Epigenetic Silencing of the p16 Tumor Suppressor Is Associated with Loss of CTCF Binding and a Chromatin BoundaryMolecular Cell, 2009
- Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivoBritish Journal of Cancer, 2009
- Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene ExpressionCancer Cell, 2008
- HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombinationProceedings of the National Academy of Sciences, 2007
- Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applicationsJournal of Cellular Physiology, 2007
- Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markersBritish Journal of Cancer, 2007
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004
- The power and the promise of DNA methylation markersNature Reviews Cancer, 2003
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002
- HuR and mRNA stabilityCellular and Molecular Life Sciences, 2001